EMMs are a broad family of molecules that fundamentally impact and regulate human metabolism. We believe our approach to EMMs has the potential to bring about a transformation in health and medicine.
Our platform has produced a rich pipeline of AXA candidates with programs in liver, muscle, and blood. We are developing our lead AXA Candidate, AXA1665 as a drug product for hepatic encephalopathy (HE). We have not made a development path decision for our other AXA Candidates.
*Axcella conducts Non-IND, IRB-approved Clinical studies to evaluate the safety and tolerability of its AXA candidates in human subjects, or effects on the normal structure or function of the body. Studies intended at the time of initiation to support drug development will be conducted under an IND.
Our approach to the development of our AXA Candidates translates complex human biology into potential drug product and non-drug† candidates that modulate metabolism.
†As used on this website, non-drug product means a non-therapeutic use of an AXA Candidate. Such use may be as a functional food product or dietary supplement.
